Lei Di.com Lei Jianping September 21
Enwei Pharmaceutical Co., Ltd. (referred to as "Enwei Pharmaceutical", stock code: 301331) was listed on the Shenzhen Stock Exchange today.
Enwei Pharmaceutical issued 17.54 million shares this time, with an issue price of 29.80 yuan and raised 523 million yuan.
Enwei Pharmaceutical opens at 42 yuan and closes at 43.73 yuan, and the closing price is 46% higher than the issue price; based on the closing price, the company's market value is 3.067 billion yuan.
Nearly half of the revenue comes from Jieeryin Washing Liquid
Enwei Pharmaceutical is mainly engaged in the research, development, production and sales of traditional Chinese patent medicines and chemical drugs. Its products operated by it cover a variety of fields such as gynecological products, pediatric medicines, and respiratory medicines. The company has 17 core products including Jieeryin Lotion Liquid, Jieeryin Ointment, Jieeryin Effervescent Tablets, Shanmai Jianpi Oral Liquid, Qingjing Capsules, Danxiong Tongmai Granules, etc.
Among them, the company has been deeply engaged in the field of gynecological products for many years. Minnei.com data shows that from 2017 to 2021, the core product "Jieryin Lotion" ranked first in the field of Chinese patent medicine for gynecological inflammation in urban retail pharmacies in China.
prospectus shows that Enwei Pharmaceutical's revenue in 2019, 2020 and 2021 was RMB 620 million, RMB 634 million and RMB 680 million, respectively; net profit was RMB 91.577 million, RMB 105 million and RMB 102 million, respectively; net profit after deducting non-operating items was RMB 70.32 million, RMB 79.97 million and RMB 84.55 million, respectively.
During the reporting period, the company's core product "Jieryin Washing" revenue was RMB 314 million, RMB 320 million and RMB 323 million, respectively, accounting for 50.64%, 50.66% and 47.56% of the company's operating income, respectively.
Enwei Pharmaceutical expects revenue from January to September 2022 to be approximately RMB 460 million to RMB 500 million, a year-on-year increase of approximately -5.49% to 2.73%; it is expected to achieve a net profit attributable to parent company shareholders of approximately RMB 56 million to RMB 66 million, a year-on-year increase of approximately -14.48% to 0.79%; it is expected to achieve a net profit attributable to non-operating items of approximately RMB 48 million to RMB 58 million, a year-on-year increase of approximately -16.70% to 0.65%.
is the first to be held in Xue Yongxin’s family business, before the IPO of
, Xue Yongxin, Xue Yongjiang, Xue Gang and Xue Weihong indirectly controlled 89.6521% of Enwei Pharmaceutical’s equity through Enwei Group, Chengdu Jiewei, Chengdu Zehong, Chengdu Ruijinheng and Changdu Jieweit, and are the actual controllers of Enwei Pharmaceutical.
Among them, Enwei Group holds 38.1951%, Chengdu Jiewei, Chengdu Zehong and Chengdu Ruijinheng hold 16.5509% of the shares, Changdu Jieweite holds 1.8043%, Changdu Longwei holds 1.6249%, CSI Investment holds 1.598%, Changdu Xiangwei holds 1.4567%, Jinshi Yikang holds 1.4020%, Changdu Jiwei holds 1.1902%, Changdu Changwei holds 1.1361%, Changdu Huiwei holds 1.0670%, and Changdu Shengwei holds 0.8730%.
Xue Yongxin and Xue Yongjiang are brothers, Xue Yongxin and Xue Gang and Xue Weihong are father-son relationships, and Xue Gang and Xue Weihong are brothers.
Xue Yongxin, male, born in March 1952, served as the director of Chengdu Shuangliu Tuanjie Wood Factory from 1983 to 1985; from 1985 to 1986, served as the director of Chengdu Shuangliu Experimental Chemical Factory; from 1986 to 2013, he served as the executive director and general manager of Chengdu Enwei Chemical Company, Chengdu Enwei Chemical Co., Ltd., and Enwei Group; from 2010 to June 2020, he served as the executive director and general manager of Enwei Pharmaceuticals; from 2014 to the present, he served as the general manager of Enwei Group.
Xue Yongjiang, male, born in March 1971, with a master's degree in business administration, Columbia University School of Business. From 1987 to 1995, he served as assistant president, sales manager of Chengdu Enwei Pharmaceutical Co., Ltd. and general manager of Chengdu Enwei Health Pharmaceutical Co., Ltd.; from 1995 to 2003, he served as general manager of Enwei Group's American branch; from 2004 to 2005, he served as president of Enwei Group and Enwei Pharmaceutical; from 2005 to 2018, he served as president of Enwei Pharmaceutical, executive director and general manager of Enwei Pharmaceutical. Since 2018, he has served as the company's chairman and CEO.
Xue Gang, male, born in October 1973, has permanent residence in Singapore. From 1997 to 2005, he served as the general manager of Chengdu Enwei Pharmaceutical Co., Ltd. and Hainan Enwei Pharmaceutical Co., Ltd.; from 2002 to 2010, he served as the executive director and manager of Chengdu Enwei Pharmaceutical Chain Co., Ltd.; from 2002 to 2017, he served as the executive director and general manager of Chengdu Enwei Medical Trade; from 2010 to 2017, he served as the manager and executive director of Chengdu Linglong Shangpin Real Estate Development Co., Ltd.; from 2013 to June 2020, he served as the director of Enwei Pharmaceutical; from 2018 to the present, he served as the vice chairman and president of the company.
Xue Weihong, male, born in June 1977, Hong Kong resident (non-permanent), from 1998 to 1999, served as the marketing manager of Chengdu Enwei Pharmaceutical Co., Ltd.; from 2000, served as the assistant to the president of Enwei Group; in 2001, served as the general manager of the medical business department of Enwei Group; in 2002, served as the director of the marketing department of Chengdu Enwei Pharmaceutical Co., Ltd.; from 2003 to 2005, served as the general manager of Hainan Zehong Advertising Co., Ltd.; from 2006 to 2008 , served as the general manager of Chengdu Enwei Daoyuan Shengcheng Tourism Development Co., Ltd.;
Xue Weihong has served as the general manager and chairman of Dayi County Hemingshan Daoyuan Water Co., Ltd., Chengdu Zehong Pharmaceutical Research and Development Co., Ltd., Panzhihua Shuhong Trading Co., Ltd., Sichuan Shuhong Wine Co., Ltd., Chengdu Zehong Brand Marketing Planning Co., Ltd., Chengdu Yuechuang Network Technology Co., Ltd., Hainan Zehong Advertising Co., Ltd. and other companies; from 2018 to the present, he has served as the director of the company. After the IPO of
, Enwei Group held 28.6434%, Chengdu Jiewei, Chengdu Zehong and Chengdu Ruijinheng held 12.4119%, Chamdo Jieweit held 1.3531%, and Chamdo Longwei held 1.2185%.
——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
